Skip to content

Microdosing research published in 2023

28 studies whose primary subject is microdosing were published in 2023, up from 27 in 2022. Newest first. Back to the microdosing overview

Studies

Novel Application of Microdosing Glucagon for Hypoglycemia After Total Pancreatectomy and Autologous Islet Transplant

JCEM Case Reports December 15, 2023 Ebne Rafi, Claudia Lewis, Betul Hatipoglu

Abstract Total pancreatectomy and autologous islet transplantation (TPAIT) is a procedure to ameliorate dysglycemia associated with post-pancreatectomy. Patients who undergo TPAIT are at risk of developing hypoglycemia postoperatively. The current literature suggests that hypoglycemia may be due to a glucagon-deficiency state. To date, there is minimal literature available that explores...

Managing expectations with psychedelic microdosing

npj Mental Health Research November 8, 2023 Omer A. Syed, Benjamin Tsang 4 citations

The recent years have seen an unprecedented surge of psychedelic research. Studies with psilocybin (colloquially known as magic mushrooms), in particular, have shown promise in ameliorating symptoms of treatment-refractory depression, anxiety, and substance use disorder, among others 1 , 2 . Microdosing, the practice of regularly taking roughly a tenth of full psychedelic doses, is becoming...

DOI: 10.1038/s44184-023-00044-9 (opens in new tab) Full text (opens in new tab) Recreational use Mental health Applied psychology Psychotherapist

Psycholytic dosing or 'microdosing' of Amanita muscaria (red fly agaric) mushrooms—A retrospective case study

PsyArXiv November 7, 2023 Mika Turkia 2 citations preprint

Following advice received in a dream, a woman in her early thirties, suffering from depression, anxiety, and sleep disorders caused by complex trauma in her childhood, experimented with 'microdosing' or psycholytic dosing of Amanita muscaria (fly agaric) mushrooms. During a 3.5-month period with an intuition-based, gradually declining dosing scheme, her symptoms significantly decreased. No...

Microdosing ketamine in Drosophila does not inhibit SERT like SSRIs, but causes behavioral changes mediated by glutamate and serotonin receptors

bioRxiv Preprint Server November 7, 2023 Kelly E. Dunham, Kani H. Khaled, Leah Weizman et al. preprint

Recently, the FDA approved microdosing ketamine for treatment resistant depression. Traditional antidepressants, like serotonin selective reuptake inhibitors (SSRIs), block serotonin reuptake, but it is not clear if ketamine blocks serotonin reuptake. Here, we tested the effects of feeding ketamine and SSRIs to Drosophila melanogaster larvae, which has a similar serotonin system to mammals, and...

Trait mindfulness and personality characteristics in a microdosing ADHD sample: a naturalistic prospective survey study

Frontiers in Psychiatry October 16, 2023 Eline Haijen, Petra P M Hurks, Kim P. C. Kuypers 6 citations

Background Microdosing (MD), repeatedly taking psychedelics in small, non-hallucinogenic amounts, has been practiced by individuals to relieve attention deficit hyperactivity disorder (ADHD) symptoms. Generally, adults diagnosed with ADHD have lower levels of mindfulness and differ in personality structure from non-ADHD adults. How MD affects mindfulness and personality in adults with ADHD...

DOI: 10.3389/fpsyt.2023.1233585 (opens in new tab) Mindfulness Personality Conscientiousness Clinical psychology +4

An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1).

Pilot and Feasibility Studies October 5, 2023 Carina Joy Donegan, Dimitri Daldegan-Bueno, Rachael Sumner et al. 23 citations

Globally, an estimated 260 million people suffer from depression [1], and there is a clear need for the development of new, alternative antidepressant therapies. In light of problems with the tolerability and efficacy of available treatments [2], a global trend is emerging for patients to self-treat depression with microdoses of psychedelic drugs such as lysergic acid diethylamide (LSD) and...

Acute Mood-Elevating Properties of Microdosed Lysergic Acid Diethylamide in Healthy Volunteers: A Home-Administered Randomized Controlled Trial.

Biological Psychiatry September 15, 2023 Robin J Murphy, Rachael Sumner, William Evans et al. 69 citations

Microdosing psychedelic drugs is a widespread social phenomenon with diverse benefits claimed for mood and cognition. Randomized controlled trials have failed to support these claims, but the laboratory-based dosing in trials conducted to date may have limited ecological validity. Healthy male volunteers were randomized into lysergic acid diethylamide (LSD) (n = 40) and placebo (n = 40) groups...

Microdosing psychedelics: The segregation of spiritual and scientific narratives within the r/microdosing online community

Journal of Psychedelic Studies September 11, 2023 Ioana Pop, Erwin Gielens, Hannah Kottmann 1 citation

Abstract Background and aims Microdosing psychedelics refers to the practice of repeatedly ingesting doses that do not reach the threshold for perceptual alterations. This practice has gained attention from mass media, businesses, and the general public, as evidenced by the proliferation of online communities dedicated to it. In this contribution, we examine the content generated within the...

DOI: 10.1556/2054.2023.00260 (opens in new tab) Full text (opens in new tab) Narrative Spirituality Perception Cognition +1

Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats.

Molecular Psychiatry September 1, 2023 Kat F. Kiilerich, Joe Lorenz, Malthe B. Scharff et al. 48 citations

Psilocybin (a classic serotonergic psychedelic drug) has received appraisal for use in psychedelic-assisted therapy of several psychiatric disorders. A less explored topic concerns the use of repeated low doses of psychedelics, at a dose that is well below the psychedelic dose used in psychedelic-assisted therapy and often referred to as microdosing. Psilocybin microdose users frequently report...

The risk of chronic psychedelic and MDMA microdosing for valvular heart disease

Journal of Psychopharmacology August 12, 2023 Michael Tagen, Daniel Mantuani, Alex Holstein et al. 39 citations

Psychedelic microdosing is the practice of taking very low doses of psychedelic substances, typically over a longer period of time. The long-term safety of chronic microdosing is relatively uncharacterized, but valvular heart disease (VHD) has been proposed as a potential risk due to activation of the serotonin 5-HT 2B receptor. However, this risk has not yet been comprehensively assessed. This...

Rational Design, Synthesis, and Characterization of a Solid Δ9-Tetrahydrocannabinol Nanoformulation Suitable for “Microdosing” Applications

Cannabis and Cannabinoid Research August 9, 2023 Abhinandan Banerjee, William Hosie, Ana Carolina Terso Ventura et al.

Background: This article highlights the formulation of a solid Δ9-tetrahydrocannabinol (THC)-loaded ingestible prepared from pure THC distillate. Methods: A THC-containing ethanol-assisted cannabinoid nanoemulsion (EACNE) was created using a solvent displacement technique. Subsequently, the EACNE was converted to a solid powdery material while still retaining its THC potency, a format uniquely...

Microdosing psychedelics has no impact on cognitive function in naturalistic settings

Journal of Psychology & Clinical Psychiatry August 1, 2023 Jannis Dinkelacker, Ioana Pop 3 citations

Background and aim: Subjective and anecdotal accounts link ingestion of psychedelic microdoses, quantities small enough to retain perceptual clarity, to enhanced cognitive function and performance. In this study we review current evidence, test the link between domains of cognitive function and microdosing psychedelics and evaluate a remote testing approach for cognitive function. Methods: In...

The difference between 'placebo group' and 'placebo control': a case study in psychedelic microdosing.

Scientific Reports July 26, 2023 Balázs Szigeti, David Nutt, Robin Carhart-Harris et al. 33 citations

In medical trials, 'blinding' ensures the equal distribution of expectancy effects between treatment arms in theory; however, blinding often fails in practice. We use computational modelling to show how weak blinding, combined with positive treatment expectancy, can lead to an uneven distribution of expectancy effects. We call this 'activated expectancy bias' (AEB) and show that AEB can inflate...

DOI: 10.1038/s41598-023-34938-7 (opens in new tab) Placebo effect Expectation bias Mind-body connection Psychological impact +14

In healthy adults, microdosing of LSD produced transient effects on mood

The Brown University Psychopharmacology Update July 1, 2023

A randomized trial involving healthy adult men has found that microdosing of lysergic acid diethylamide (LSD) over a 6‐week period resulted in improved effects on mood during dose days. No longer‐term improvements in mood or cognition were reported. Study results were published online March 28, 2023, in Biological Psychiatry.

Microdosing: A Conceptual Framework for use as Programming Strategy for Resistance Training in Team Sports

Strength & Conditioning Journal June 15, 2023 M. Cuthbert, G. G. Haff, J. McMahon et al.

Supplemental Digital Content is Available in the Text. ABSTRACT Microdosing, in the context of resistance training, has increased in popularity within sporting environments where it is frequently used among strength and conditioning professionals. Although there is a clear definition for the concept within the literature, it is still commonly incorrectly used, and the extent to which...

Is Microdosing a Placebo?

June 4, 2023 Vince Polito, Paul Liknaitzky 2 citations preprint

Some recent research and commentary have suggested that most or all the effects reported by people who microdose psychedelics may be explained by expectations or placebo effects. Here we step through all the available evidence from dose-controlled studies that have investigated the effects of low doses of LSD and psilocybin. We suggest eight reasons why current claims that microdosing is...

DOI: 10.31234/osf.io/3ykst (opens in new tab) Full text (opens in new tab) Placebo Expectancy theory Microdose Dose dependence +2

17 Microdosing/microtracer based pediatric drug development

Archives of Disease in Childhood June 1, 2023 Esther van Duijn, Steven Erpelinck, Wouter Vaes

Introduction: An overview is given on the use of microdosing/microtracing studies for the safer and faster development of drugs in children. In a microdosing study a very small amount of radiolabelled (often 14C) drug is administered to a human volunteer. Using accelerator mass spectrometry extremely low amounts of the drug and metabolites can be traced and quantified. Methods: Several...

Evaluation of the Effect of Stone Lines and Microdosing Adoption on Sorghum Yield and Income: A Case of Smallholder Farmers in Burkina Faso

Journal of Agricultural Sciences May 15, 2023 Didier Sawadogo, Ichizen Matsumura, K. Yasunobu et al.

This present study aims to investigate the factors influencing the combined adoption of stone lines and microdosing and its effect on sorghum yields and net income. By adjusting for biases in observable and unobservable factors, the multinomial endogenous switching regression (MESR) model was employed to estimate the net effects of adoption on outcomes. The average treatment effect on treated...

Experiences of microdosing psychedelics in an attempt to support wellbeing and mental health.

BMC Psychiatry March 14, 2023 Rebecca S Ryan, Alex Copello, Andrew P Fox 12 citations

Microdosing psychedelic drugs is a growing phenomenon, but little is known about the experiences surrounding this. Research broadly suggests that people may use psychedelics in an attempt to self-medicate for mental health and wellbeing. However, the precise details, rationale and meaning of such attempts remains unclear, and would benefit from clarification, using tailored experiential...

Transitioning From High-dose Methadone to Buprenorphine Using a Microdosing Approach: Unique Considerations at ASAM Level 3 Facilities

Journal of Addiction Medicine March 1, 2023

Transitions from high-dose methadone to buprenorphine for treatment of opioid use disorder (OUD) present risk of precipitated withdrawal related to the introduction of a high-affinity partial agonist at the mu-opioid receptor after occupancy by a lower-affinity full agonist. Various strategies have been explored to maintain patient stability during this process, including microdosing...